Skip to main content

A Phase I, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 as a single agent in relapsed or refractory hematological malignancies and in combgination with Daratumumab as a Salvage Regimen for Multiple Myeloma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Nektar Therapeutics

Start Date

January 30, 2020

End Date

February 14, 2025
 

Administered By

Duke Cancer Institute

Awarded By

Nektar Therapeutics

Start Date

January 30, 2020

End Date

February 14, 2025